MedTrace Logo

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

NCT00098852 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-01-06

No results posted yet for this study

Summary

RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine.

PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.

Conditions

Interventions

DRUG

rosiglitazone maleate

Sponsors & Collaborators

Principal Investigators

  • Electron Kebebew, MD · University of California, San Francisco

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00098852 on ClinicalTrials.gov